BACKGROUND AND PURPOSE: Vasodilatation may contribute to the neuroprotective and vascular anti-remodelling effect of the tissue transglutaminase 2 (TG2) inhibitor cystamine. Here, we hypothesized that inhibition of TG2 followed by blockade of smooth muscle calcium entry and/or inhibition of Rho kinase underlies cystamine vasodilatation. EXPERIMENTAL APPROACH: We used rat mesenteric small arteries and RT-PCR, immunoblotting, and measurements of isometric wall tension, intracellular Ca(2+) ([Ca(2+)]i ), K(+) currents (patch clamp), and phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) and myosin regulatory light chain, in our experiments. KEY RESULTS: RT-PCR and immunoblotting revealed expression of TG2 in mesenteric small arteries. Cystamine concentration-dependently inhibited responses to phenylephrine, 5-HT and U46619 and for extracellular potassium. Selective inhibitors of TG2, LDN 27129 and T101, also inhibited phenylephrine contraction. An inhibitor of PLC suppressed cystamine relaxation. Cystamine relaxed and reduced [Ca(2+)]i in phenylephrine-contracted arteries. In potassium-contracted arteries, cystamine induced less relaxation without changing [Ca(2+)]i , and these relaxations were blocked by mitochondrial complex inhibitors. Blockers of Kv 7 channels, XE991 and linopirdine, inhibited cystamine relaxation and increases in voltage-dependent smooth muscle currents. Cystamine and the Rho kinase inhibitor Y27632 reduced basal MYPT1-Thr(855) phosphorylation, but only Y27632 reduced phenylephrine-induced increases in MYPT1-Thr(855) and myosin regulatory light chain phosphorylation. CONCLUSIONS AND IMPLICATIONS: Cystamine induced vasodilatation by inhibition of receptor-coupled TG2, leading to opening of Kv channels and reduction of intracellular calcium, and by activation of a pathway sensitive to inhibitors of the mitochondrial complexes I and III. Both pathways may contribute to the antihypertensive and neuroprotective effect of cystamine.
BACKGROUND AND PURPOSE: Vasodilatation may contribute to the neuroprotective and vascular anti-remodelling effect of the tissue transglutaminase 2 (TG2) inhibitor cystamine. Here, we hypothesized that inhibition of TG2 followed by blockade of smooth muscle calcium entry and/or inhibition of Rho kinase underlies cystamine vasodilatation. EXPERIMENTAL APPROACH: We used rat mesenteric small arteries and RT-PCR, immunoblotting, and measurements of isometric wall tension, intracellular Ca(2+) ([Ca(2+)]i ), K(+) currents (patch clamp), and phosphorylation of myosin phosphatase targeting subunit 1 (MYPT1) and myosin regulatory light chain, in our experiments. KEY RESULTS: RT-PCR and immunoblotting revealed expression of TG2 in mesenteric small arteries. Cystamine concentration-dependently inhibited responses to phenylephrine, 5-HT and U46619 and for extracellular potassium. Selective inhibitors of TG2, LDN 27129 and T101, also inhibited phenylephrine contraction. An inhibitor of PLC suppressed cystamine relaxation. Cystamine relaxed and reduced [Ca(2+)]i in phenylephrine-contracted arteries. In potassium-contracted arteries, cystamine induced less relaxation without changing [Ca(2+)]i , and these relaxations were blocked by mitochondrial complex inhibitors. Blockers of Kv 7 channels, XE991 and linopirdine, inhibited cystamine relaxation and increases in voltage-dependent smooth muscle currents. Cystamine and the Rho kinase inhibitor Y27632 reduced basal MYPT1-Thr(855) phosphorylation, but only Y27632 reduced phenylephrine-induced increases in MYPT1-Thr(855) and myosin regulatory light chain phosphorylation. CONCLUSIONS AND IMPLICATIONS: Cystamine induced vasodilatation by inhibition of receptor-coupled TG2, leading to opening of Kv channels and reduction of intracellular calcium, and by activation of a pathway sensitive to inhibitors of the mitochondrial complexes I and III. Both pathways may contribute to the antihypertensive and neuroprotective effect of cystamine.
Authors: Kyle B Johnson; Humphrey Petersen-Jones; Janice M Thompson; Kiyotaka Hitomi; Miho Itoh; Erik N T P Bakker; Gail V W Johnson; Gozde Colak; Stephanie W Watts Journal: Am J Physiol Heart Circ Physiol Date: 2012-02-03 Impact factor: 4.733
Authors: Shaojie Han; John E Speich; Thomas J Eddinger; Krystina M Berg; Amy S Miner; Chris Call; Paul H Ratz Journal: Am J Physiol Heart Circ Physiol Date: 2006-02-03 Impact factor: 4.733
Authors: E R Hedegaard; B D Nielsen; A Kun; A D Hughes; C Krøigaard; S Mogensen; V V Matchkov; O Fröbert; U Simonsen Journal: Br J Pharmacol Date: 2014-01 Impact factor: 8.739
Authors: Erik N T P Bakker; Carsten L Buus; Jos A E Spaan; Jop Perree; Anuradha Ganga; Titia M Rolf; Oana Sorop; Linda H Bramsen; Michael J Mulvany; Ed Vanbavel Journal: Circ Res Date: 2004-11-18 Impact factor: 17.367
Authors: Thomas M Jeitner; E James Delikatny; Jenny Ahlqvist; Hugh Capper; Arthur J L Cooper Journal: Biochem Pharmacol Date: 2005-03-15 Impact factor: 5.858
Authors: Thomas A Jepps; Preet S Chadha; Alison J Davis; Maksym I Harhun; Gillian W Cockerill; Søren P Olesen; Rie S Hansen; Iain A Greenwood Journal: Circulation Date: 2011-07-11 Impact factor: 29.690
Authors: Jocelyn A Silvester; Elizabeth A Faucher; Caitlin E McCarty; Adie Kalansky; Zackary J Hintze; Paul D Mitchell; Jeffrey D Goldsmith; Dascha C Weir; Alan M Leichtner Journal: J Pediatr Gastroenterol Nutr Date: 2019-02 Impact factor: 2.839
Authors: Huilei Wang; James Chen; Sandeep Jandu; Sean Melucci; William Savage; Kavitha Nandakumar; Sara K Kang; Sebastian Barreto-Ortiz; Alan Poe; Shivam Rastogi; Maria Bauer; Jochen Steppan; Lakshmi Santhanam Journal: Cell Death Discov Date: 2021-07-29